introductio: hematopoietic stem cell transplants (hsct) are considered as treatment options for patients with solid tumors. transplant numbers have changed significantly over the last decade. we have done autologous and allogeneic hsct for treatment of solid tumor patients in our center. methods: in order to show the transplant effect on solid tumor treatment, we collected data from 71 patients...

introduction: allogeneic hematopoietic stem cell transplantation is a potentially curative treatment modality for hematological malignancies. we evaluated the outcome of patients suffering from hematological malignancies, including acute leukemias, chronic myeloid leukemia and myelodysplastic syndrome after allogeneic transplantation. methods: all patients having hematological malignancies with...

introduction: acute myelogenous leukemia (aml) is a clonal  malignant disease of hematopoietic tissue. the early use of  hematopoietic stem cell transplantation (hsct) for aml was for patients with advanced stages of disease, usually while in relapse, in second or subsequent remission, or with resistant disease. patients and methods: from march 1991 until february 2008, 356(65%) registered allo...

introduction: the traditional goal of the treatment of acute myelogenous leukemia is to produce and maintain a complete remission (cr).the difference in survival time was entirely attributable to the duration of time spent in cr .in this study, the outcome of aml patients with allogeneic hsct in cr1 versus other than cr1 was compared. patients and methods: since march 1991 until november 2008, ...

Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...

introduction: this review reports the current results of hematopoietic stem cell transplantation (hsct) in patients who had received transplantation in the hematology-oncology and sct research center, tehran, iran. methods: in iran, from 1991 through 2010, a total of 3170 hematopoietic stem cell transplantation have been carried out. the male/female patient ratio was 1909/1261 with a median age...

introduction: acute promyelocytic leukemia treatment revolutionized by new tretamnets. currently number of patinets who undergoe hematopoietic stem cell transplantation decrased so experience with this modality is limited. here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients. design and setting: retrospective, single center methods: between year ...

the  non-classical mhc  class-i mainly involves in the  regulation of  innate  immune responses where hla-e  plays a significant role in the cell identification by natural killer cells. hla-e is a main regulatory ligand for natural killer cells and given the importance of these effector cells in hematopoietic stem cell transplantation, we investigated the effect of hla-e polymorphisms on post-h...

hematology- oncology and stem cell transplantation research center related to tehran university of medical sciences located in shariati hospital. these center activities have started in 1991 in order to help needful patients and augment new data to reach new aspects of therapeutic trials. also it is one of the greatest stem cell transplantation centers in world and is the second center in the w...

introduction: allogeneic hematopoietic stem cell transplantation (hsct) has been reported to be a successful curative treatment in aml patients. myeloablative conditioning (mac) is used more frequent as a preparing regimen. this study attempts to compare the outcome of patients who has received mac and reduced- intensity conditioning (ric). methods: totally, 618 patients with aml underwent hsct...